Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: passagebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2024 | $3.00 → $4.00 | Outperform | Wedbush |
| 9/3/2024 | $7.00 | Buy | Rodman & Renshaw |
| 3/8/2022 | Overweight → Neutral | JP Morgan | |
| 3/4/2022 | $29.00 → $24.00 | Outperform | Raymond James |
| 1/19/2022 | $29.00 → $6.00 | Buy → Neutral | Goldman |
| 7/1/2021 | $29.00 | Outperform | Raymond James |